Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis

<p><strong>Background:</strong> multiple sclerosis modifying drugs are intended to reduce the frequency of relapses, delay the progression of disability, as well as the appearance of new lesions in the Central Nervous System.<br /><strong>Objective:</strong> to de...

Full description

Saved in:
Bibliographic Details
Main Authors: Làzaro Aurelio Vàzquez Gòmez, Carlos Hidalgo Mesa, Yunier Broche Pèrez, Yanet Valdés Morales
Format: Article
Language:Spanish
Published: Centro Provincial de Información de Ciencias Médicas. Cienfuegos 2022-10-01
Series:Medisur
Subjects:
Online Access:http://medisur.sld.cu/index.php/medisur/article/view/5396
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832576882594283520
author Làzaro Aurelio Vàzquez Gòmez
Carlos Hidalgo Mesa
Yunier Broche Pèrez
Yanet Valdés Morales
author_facet Làzaro Aurelio Vàzquez Gòmez
Carlos Hidalgo Mesa
Yunier Broche Pèrez
Yanet Valdés Morales
author_sort Làzaro Aurelio Vàzquez Gòmez
collection DOAJ
description <p><strong>Background:</strong> multiple sclerosis modifying drugs are intended to reduce the frequency of relapses, delay the progression of disability, as well as the appearance of new lesions in the Central Nervous System.<br /><strong>Objective:</strong> to determine the early indicators of response to treatment with IFNb-1a.<br /><strong>Methods:</strong> Observational, analytical longitudinal prospective cohort study in patients diagnosed with multiple sclerosis. Two study cohorts were formed, each with 39 patients.<br /><strong>Results:</strong> the mean and standard deviation of the expanded disability status scale at 36 months was 2.37 ± 1.86 in the study group and 3.15 ± 2.1 in the control group. In the outbreaks of .13 ± .33 in the study group and in the control group of .41 ± .59. New lesions in T2 after the first 12 months of treatment was 0.90 ± 1.16 for the study group and 1 ± 1.10 for the control. Extended-scale progression of disability status, pretreatment annualized relapse rate, age of disease onset, time since disease progression, and gadolinium-enhancing lesions were significantly associated with the odds ratio of older Probability of non-progression for the study group with respect to the control group for the combined variable progression by extended disability status scale and relapses.<br /><strong>Conclusions:</strong> early indicators of response to treatment with interferon beta-1a were identified; that help assess the response to treatment early, which has a positive impact on the evolution of the disease.</p>
format Article
id doaj-art-3369943653fb4a6398fffeb30b914d1a
institution Kabale University
issn 1727-897X
language Spanish
publishDate 2022-10-01
publisher Centro Provincial de Información de Ciencias Médicas. Cienfuegos
record_format Article
series Medisur
spelling doaj-art-3369943653fb4a6398fffeb30b914d1a2025-01-30T21:28:59ZspaCentro Provincial de Información de Ciencias Médicas. CienfuegosMedisur1727-897X2022-10-012058258332181Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosisLàzaro Aurelio Vàzquez Gòmez0Carlos Hidalgo Mesa1Yunier Broche Pèrez2Yanet Valdés Morales3Hospital Provincial Universitario Clínico-Quirúrgico Arnaldo Milián Castro. Santa Clara, Villa Clara. Cuba.Hospital Universitario Militar Clínico-Quirúrgico Manuel Piti Fajardo. Villa Clara. Cuba.Universidad Central Martha Abreus de las Villas. Cuba.Hospital Provincial Universitario Clínico-Quirúrgico Arnaldo Milián Castro. Santa Clara, Villa Clara. Cuba.<p><strong>Background:</strong> multiple sclerosis modifying drugs are intended to reduce the frequency of relapses, delay the progression of disability, as well as the appearance of new lesions in the Central Nervous System.<br /><strong>Objective:</strong> to determine the early indicators of response to treatment with IFNb-1a.<br /><strong>Methods:</strong> Observational, analytical longitudinal prospective cohort study in patients diagnosed with multiple sclerosis. Two study cohorts were formed, each with 39 patients.<br /><strong>Results:</strong> the mean and standard deviation of the expanded disability status scale at 36 months was 2.37 ± 1.86 in the study group and 3.15 ± 2.1 in the control group. In the outbreaks of .13 ± .33 in the study group and in the control group of .41 ± .59. New lesions in T2 after the first 12 months of treatment was 0.90 ± 1.16 for the study group and 1 ± 1.10 for the control. Extended-scale progression of disability status, pretreatment annualized relapse rate, age of disease onset, time since disease progression, and gadolinium-enhancing lesions were significantly associated with the odds ratio of older Probability of non-progression for the study group with respect to the control group for the combined variable progression by extended disability status scale and relapses.<br /><strong>Conclusions:</strong> early indicators of response to treatment with interferon beta-1a were identified; that help assess the response to treatment early, which has a positive impact on the evolution of the disease.</p>http://medisur.sld.cu/index.php/medisur/article/view/5396esclerosis múltipleesclerosis múltiple remitente-recurrenteinterferón beta-1a
spellingShingle Làzaro Aurelio Vàzquez Gòmez
Carlos Hidalgo Mesa
Yunier Broche Pèrez
Yanet Valdés Morales
Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
Medisur
esclerosis múltiple
esclerosis múltiple remitente-recurrente
interferón beta-1a
title Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
title_full Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
title_fullStr Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
title_full_unstemmed Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
title_short Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
title_sort response to treatment with interferon beta 1a in patients with relapsing remitting multiple sclerosis
topic esclerosis múltiple
esclerosis múltiple remitente-recurrente
interferón beta-1a
url http://medisur.sld.cu/index.php/medisur/article/view/5396
work_keys_str_mv AT lazaroaureliovazquezgomez responsetotreatmentwithinterferonbeta1ainpatientswithrelapsingremittingmultiplesclerosis
AT carloshidalgomesa responsetotreatmentwithinterferonbeta1ainpatientswithrelapsingremittingmultiplesclerosis
AT yunierbrocheperez responsetotreatmentwithinterferonbeta1ainpatientswithrelapsingremittingmultiplesclerosis
AT yanetvaldesmorales responsetotreatmentwithinterferonbeta1ainpatientswithrelapsingremittingmultiplesclerosis